Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.64 |
| ▸ | MAOA | P21397 | 6/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.51 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17185524 | 0.91 | ABCB1 (0.75) | MAOBMAOAABCB1MEN1ALDH1A1 | |
| SCHEMBL19129531 | 0.89 | MAOB (0.67) | MAOBMAOAABCB1ADORA3MEN1 | |
| SCHEMBL19129537 | 0.89 | MAOB (0.64) | MAOBMAOAABCB1ADORA3MEN1 | |
| SCHEMBL19129742 | 0.88 | MAOB (0.62) | MAOBMAOAABCB1ADORA3MEN1 | |
| SCHEMBL19129536 | 0.87 | ACHE (0.63) | MAOBMAOAABCB1ADORA3 | |
| SCHEMBL19129741 | 0.87 | MAOB (0.61) | MAOBMAOAABCB1ADORA3 | |
| SCHEMBL19129506 | 0.86 | MAOB (0.60) | MAOBMAOAABCB1ADORA3 | |
| SCHEMBL20100895 | 0.86 | ABCB1 (0.82) | MAOBMAOAABCB1ADORA3MEN1 | |
| SCHEMBL19129504 | 0.83 | MAOB (0.79) | MAOBMAOAABCB1ADORA3MEN1 | |
| SCHEMBL19129478 | 0.83 | ACHE (0.64) | MAOBMAOAABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868715-B2 | Apigenin analogs, compositions, and methods related thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170204078-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204078-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | CBS, CTH, PTGIS | MAOB 1245/4885MAOA 1595/4885ABCB1 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.